WEDNESDAY, Oct. 16, 2024 (HealthDay News) -- The U.S. Food and Drug Administration approved Itovebi (inavolisib), in ...

A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.

The FDA has approved Genentech’s Itovebi™ (inavolisib) as a targeted therapy for adults with advanced hormone ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...

Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after ...

In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.

The test is approved for patients with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

The FDA has approved Itovebi in combination with palbociclib and fulvestrant to treat certain patients with PIK3CA-mutant breast cancer.

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...

The FDA also approved the FoundationOne Liquid CDx assay to identify patients who qualify for the newly approved treatment.